Hird, A. E. (2020) “Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model”, Canadian Urological Association Journal, 14(9), pp. E418–27. doi: 10.5489/cuaj.6234.